MyMD Pharmaceuticals "announced that it has executed a securities purchase agreement to raise gross proceeds of approximately $15 million in a registered direct offering of convertible preferred stock and warrants with certain accredited and institutional investors. The offering is expected to close on February 23, 2023, subject to the satisfaction of customary closing conditions. The Company engaged Katalyst Securities LLC to serve as placement agent to the Company in connection with the offering."
Published first on TheFly
